Peaking beneath the surface of recent bevacizumab trials
Nature Reviews Clinical OncologyPublished 19 April 2011
Ana M. González-Angulo, Gabriel N. Hortobágyi, Lee M. Ellis
Citations14
SJR quartileQ1
SJR score28.68
SNIP14.18
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The RIBBON-1 trial results are evaluated to ask is anti-VEGF therapy failing, and are all variables considered when scrutinizing the data?
Abstract
Does targeting VEGF improve the lives of patients with metastatic breast cancer? Since the E2100 trial, there has been uncertainty about the benefit and toxicities of anti-VEGF therapy. By evaluating the RIBBON-1 trial results, we ask is such therapy failing, and are we considering all variables when scrutinizing the data?
Keywords
Medicine
New England Journal of MedicinePaclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
3,053 Citations2007Kathy D. Miller, Molin Wang +7 more
Initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab prolongs progression-free survival, but not overall survival, as compared with pac litaxel alone.
Journal of Clinical OncologyRIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
1,061 Citations2011Nicholas J. Robert, Véronique Dièras +10 more
The combination of BV with Cape, Tax, or Anthra improves clinical benefit in terms of increased PFS in first-line treatment of metastatic breast cancer, with a safety profile comparable to prior phase III studies.
Journal of Clinical OncologyPhase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
887 Citations2010David Miles, Arlene Chan +14 more
Bvacizumab 15 mg/kg every 3 weeks significantly increased PFS when combined with docetaxel as first-line therapy for MBC compared with docentaxel plus placebo and had limited impact on the known toxicity profile of docetAXel.
JAMATreatment-Related Mortality With Bevacizumab in Cancer Patients
425 Citations2011Vishal Ranpura, Sanjaykumar Hapani +1 more
In a meta-analysis of RCTs, bevacizumab in combination with chemotherapy or biological therapy, compared with chemotherapy alone, was associated with increased treatment-related mortality.
Journal of Clinical OncologyDisease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials
159 Citations2010David Miles, Nadia Harbeck +7 more
This retrospective analysis of five placebo-controlled clinical trials does not support a decreased time to disease progression, increased mortality, or altered disease progression pattern after cessation of bevacizumab therapy.
Journal of Clinical OncologyAnalyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study
144 Citations2011Marco Colleoni, Anita Giobbie‐Hurder +15 more
Adjuvant treatment with letrozole, compared with tamoxifen, significantly reduces the risk of death, therisk of recurrent disease, and the riskof recurrence at distant sites in postmenopausal women with hormone receptor-positive breast cancer.
Journal of Clinical OncologyBevacizumab for Advanced Breast Cancer: All Tied Up With a RIBBON?
48 Citations2011Harold J. Burstein
Correlative science for effective patient selection may be the key to cost-effective treatment of cancer in the biologic therapy era.
Cancer ResearchFinal Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC).
35 Citations2009David Miles, Arlene Chan +8 more
Mature data from AVADO confirm the improvement in PFS and ORR with BV 15mg/kg combined with D compared with PL + D and suggest use of BV with 2nd-line therapy is a possible reason for lack of OS difference.
Journal of Clinical OncologyOptimal Schedule of Paclitaxel: Weekly Is Better
25 Citations2008Ana M. González-Angulo, Gabriel N. Hortobágyi
Seidman’s trial adds to the growing literature about proper scheduling of anticancer agents, specifically taxanes, with a significant increment in response rate and an important advantage in time to progression, although the study has limitations that should be considered.